Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 16/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14347657 | 1.00 | PKM (0.52) | PKMPDK1PDK2PDK3PDK4 | |
| SCHEMBL25780790 | 1.00 | PKM (0.52) | PKMPDK1PDK2PDK3PDK4 | |
| SCHEMBL993860 | 0.89 | PKM (0.61) | PKMPDK1PDK2PDK3PDK4 | |
| SCHEMBL22990996 | 0.81 | PKM (0.53) | PKMPDK1PDK2PDK3PDK4 | |
| SCHEMBL4543546 | 0.81 | EPHX2 (0.58) | PKMPDK1PDK2PDK3PDK4 | |
| SCHEMBL3273849 | 0.81 | PKM (0.53) | PKMPDK1PDK2PDK3PDK4 | |
| SCHEMBL25030253 | 0.81 | PKM (0.44) | PKMPDK1PDK2PDK3PDK4 | |
| SCHEMBL25030258 | 0.81 | PKM (0.44) | PKMPDK1PDK2PDK3PDK4 | |
| SCHEMBL3273850 | 0.81 | PKM (0.53) | PKMPDK1PDK2PDK3PDK4 | |
| SCHEMBL2342391 | 0.81 | EPHX2 (0.58) | PKMPDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2012759-B1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2010-03-10 | — | — | EP | disclosed |
| CN-101426482-A | Purine derivatives for use as adenosin A2A receptor agonists | NOVARTIS AG (CH) | 2009-05-06 | — | — | CN | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| EP-2012759-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| EP-1841768-B1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| WO-2007121923-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| EP-1841768-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006074925-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | PKM 1100/4885PDK1 880/4885PDK2 795/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | PKM 3223/4885PDK1 1986/4885PDK2 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.